Call to arrange a consultation
+1 416 777 0888
Search the site
Boehringer Ingelheim (Canada) Ltd et al. v Jamp Pharma Corportation
2022
T-2318-22
Pending
New PM(NOC) Regulations
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,557,801, 2,606,650, 2,751,833 and 2,813,661 (empagliflozin).
Counsel to:
JAMP Pharma Corporation
The decision is reported
here.
Meet the team
